Document is current
Any future updates will be listed below
-
Authors
Hope, Helen Carrasco https://orcid.org/0000-0001-5583-4510
de Sostoa, Jana
Ginefra, Pierpaolo https://orcid.org/0000-0003-3254-1269
Andreatta, Massimo https://orcid.org/0000-0002-8036-2647
Chiang, Yi-Hsuan
Ronet, Catherine
Pich-Bavastro, Christine https://orcid.org/0000-0002-6526-749X
Corria Osorio, Jesús https://orcid.org/0000-0001-6844-6170
Kuonen, François https://orcid.org/0000-0001-6137-7483
Auwerx, Johan
D’Amelio, Patrizia
Ho, Ping-Chih https://orcid.org/0000-0003-3078-3774
Carmona, Santiago J. https://orcid.org/0000-0002-2495-0671
Coukos, George https://orcid.org/0000-0001-8813-7367
Migliorini, Denis https://orcid.org/0000-0003-0151-3222
Vannini, Nicola https://orcid.org/0000-0002-6351-7512
- License Information
-
More Information
Article History
Received: 10 April 2024
Accepted: 15 April 2025
First Online: 20 May 2025
Competing interests
: Some elements of this work are part of PCT application no. PCT/EP2024/080878, titled ‘Method for suppressing CAR-T cells unresponsiveness for improving cancer immunotherapy’, for which H.C.H., P.G. and N.V. are listed as inventors. J.A. is an advisor to MetroBiotech International and Mitopower, who develop strategies to enhance NAD levels. D.M. is an inventor on patents related to CAR-T cell therapy, filed by the University of Pennsylvania and the University of Geneva, is the scientific cofounder of Cellula Therapeutics and is a consultant for Carthera, Servier Pharma, Limula and MPC Therapeutics. N.V. is a scientific advisor of Clinique La Prairie. The other authors declare no competing interests.
